Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry
- PMID: 3485113
- PMCID: PMC423499
- DOI: 10.1172/JCI112400
Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry
Abstract
Serum bone gamma-carboxyglutamic acid-containing (Gla) protein (sBGP), a sensitive and specific marker of bone turnover, was measured in 25 patients with primary hyperparathyroidism and in 24 patients with bone metastases with or without hypercalcemia. Despite similar levels of hypercalcemia, sBGP was increased in primary hyperparathyroidism (14.2 +/- 9.6 ng/ml, P less than 0.001), was decreased in malignant hypercalcemia (3.1 +/- 2.8 ng/ml, P less than 0.001), and was normal in patients with bone metastases without hypercalcemia (6.6 +/- 2.7 ng/ml). In primary hyperparathyroidism, sBGP was correlated with serum immuno-reactive parathyroid hormone (r = 0.90), calcium (r = 0.73), and with the adenoma weight (r = 0.79). After parathyroidectomy, sBGP slowly returned to normal values within 2-6 mo, suggesting that sBGP reflects increased bone turnover rather than a direct effect of parathyroid hormone on BGP synthesis at the cell level. An iliac crest biopsy was performed in 11 patients with primary hyperparathyroidism and in 9 cancer patients in a noninvaded area. sBGP was significantly correlated with all parameters reflecting bone formation but not with bone resorption. Patients with bone metastases were analyzed according to the presence or the absence of hypercalcemia. In contrast to normocalcemic patients who had normal sBGP, hypercalcemic patients had decreased sBGP (P less than 0.001) and a lower bone formation at the cellular level (P less than 0.05). Thus, biochemical and histological data suggest that an unknown humoral factor might be responsible for this uncoupling between increased resorption and decreased formation. This uncoupling, rather than local release of calcium by the metastatic process, might be responsible for hypercalcemia in patients with bone metastases.
Similar articles
-
Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.Scand J Clin Lab Invest. 1989 May;49(3):279-85. Scand J Clin Lab Invest. 1989. PMID: 2787049
-
Serum osteocalcin (BGP) in tumor-associated hypercalcemia.J Bone Miner Res. 1986 Dec;1(6):523-7. doi: 10.1002/jbmr.5650010606. J Bone Miner Res. 1986. PMID: 3509743
-
Osteocalcin and urinary hydroxyproline/creatinine ratio in the differential diagnosis of primary hyperparathyroidism and hypercalcaemia of malignancy.Scand J Clin Lab Invest. 1987 Oct;47(6):587-92. doi: 10.1080/00365518709168473. Scand J Clin Lab Invest. 1987. PMID: 3499657
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Hypercalcemia in a case of childhood acute lymphoblastic leukemia.Jpn J Clin Oncol. 1987 Dec;17(4):357-62. Jpn J Clin Oncol. 1987. PMID: 3320403 Review.
Cited by
-
Alteration in osteoblast activity and nutritional vitamin-D deficiency in non-hypercalcemic malignancy.Calcif Tissue Int. 1988 Jan;42(1):18-22. doi: 10.1007/BF02555834. Calcif Tissue Int. 1988. PMID: 3129164
-
Peptidomimetic inhibitor of L-plastin reduces osteoclastic bone resorption in aging female mice.Bone Res. 2021 Apr 9;9(1):22. doi: 10.1038/s41413-020-00135-9. Bone Res. 2021. PMID: 33837180 Free PMC article.
-
Bone Phenotyping Approaches in Human, Mice and Zebrafish - Expert Overview of the EU Cost Action GEMSTONE ("GEnomics of MusculoSkeletal traits TranslatiOnal NEtwork").Front Endocrinol (Lausanne). 2021 Dec 1;12:720728. doi: 10.3389/fendo.2021.720728. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34925226 Free PMC article. Review.
-
Evaluation of bone loss and the serum markers of bone metabolism in patients with hyperparathyroidism.Surg Today. 1995;25(7):598-604. doi: 10.1007/BF00311432. Surg Today. 1995. PMID: 7549270
-
Serum markers of bone formation in parenteral nutrition patients.Calcif Tissue Int. 1991 Aug;49(2):143-4. doi: 10.1007/BF02565139. Calcif Tissue Int. 1991. PMID: 1913294 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous